NoNO Inc.

Bioventure GNT Pharma Co., Ltd has received approval from South Korea's Ministry of Food and Drug Safety to begin a Phase III study with its first-in-class, multi-targeted stroke therapy nelonemdaz,

Hopes that a neuroprotective agent can be developed to reduce the damage caused by ischaemic stroke have received a boost, with data from a Phase II trial in the The Lancet Neurology showing promise